H. Kooreman, J. Mutsaers
1991
Citations
0
Influential Citations
0
Citations
Journal
Journal name not available for this finding
Abstract
Scientists, both in academia and industry, as well as regulatory authorities become more and more aware of the importance of enantioselectivity in drug innovation. About 25% of the medicines used to-day are racemic mixtures. The therapeutic activity nearly always resides in one of the isomers (the so-called eutomer), while the other isomer (distomer) can have an unwanted interaction with the human body; at best the distomer is a metabolic burden. Essentially the same holds true for other interactions between synthetic organic compounds and biological systems e.g. the impact of agrochemicals on ecosystems.